Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 2/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035450 | 0.84 | WEE1 (0.42) | WEE1MAP4K1KCNH2PAK4PKN1 | |
| SCHEMBL15035344 | 0.80 | CDK4 (0.41) | WEE1MAP4K1PAK4PKN1JAK2 | |
| SCHEMBL15035303 | 0.80 | WEE1 (0.44) | WEE1MAP4K1KCNH2PAK4PKN1 | |
| SCHEMBL15035411 | 0.78 | WEE1 (0.45) | WEE1MAP4K1KCNH2PAK4PKN1 | |
| SCHEMBL15041838 | 0.78 | CDK4 (0.44) | WEE1PAK4PKN1CDK4CCNA2 | |
| SCHEMBL15035346 | 0.78 | MAP4K1 (0.41) | WEE1MAP4K1KCNH2PAK4PKN1 | |
| SCHEMBL15035539 | 0.77 | FGFR1 (0.42) | PAK4PKN1CDK4CCNA2CCND1 | |
| SCHEMBL15035293 | 0.76 | CDK4 (0.51) | PAK4PKN1JAK2CDK4CCNA2 | |
| SCHEMBL15035486 | 0.74 | CDK4 (0.39) | WEE1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL15041303 | 0.74 | CDK4 (0.41) | WEE1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885MAP4K1 84/4885KCNH2 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.